HOME >> BIOLOGY >> NEWS
European researchers launch 10 million euro collaborative technology project

The European Commission has given Europe a huge boost in the field of Structural Genomics, awarding the European Molecular Biology Laboratory (EMBL) and its partners 10 Million Euro for an integrated project called "BIOXHIT."

The project aims to create a common platform throughout Europe for researchers working in the field of "biological crystallography."

BIOXHIT stands for "Biocrystallography on a Highly Integrated Technology Platform" for European Structural Genomics. The goal is to take the best of current technologies at major European centres for research in structural biology, develop them further and weave them into a single platform that integrates and standardises the best of current technology, and spread it throughout Europe.

EMBL-Hamburg will coordinate the integrated project, which unites over twenty partners from nine European countries, including all European synchrotrons. BIOXHIT combines a strongly focused research programme with networking, training and mobility of staff under a single and efficient management structure.

Biological crystallography aims to create precise, three-dimensional "architectural" models of biological molecules. Without such models at hand, it is close to impossible to understand biological processes, for instance the way proteins and other molecules behave in cells, or to design new drugs that will affect their functions. The most common method for obtaining such three-dimensional models is to bombard crystallised proteins with high-powered X-rays generated at huge synchrotron facilities.

"We already have all the single components necessary to solve molecular structures," says Victor Lamzin, grant coordinator at EMBL-Hamburg. "We have synchrotrons, we can grow protein crystals, we have the software components and we can obtain structures. But the tools we use were not originally designed for high-throughput work. This is what is needed now because of the tens of thousands of new m
'"/>

Contact: Trista Dawson
dawson@embl.de
49-6221-387-452
European Molecular Biology Laboratory
12-Feb-2004


Page: 1 2 3

Related biology news :

1. European common frog found to use novel mating strategy
2. Zoonotic diseases - European scientists unite to fight diseases
3. Second call for proposals for the European Young Investigator Award
4. Common call for action on European Research Council (ERC)
5. EURYI Award given for the first time to 25 young European researchers
6. European researchers tackle mitosis
7. Key principles for the foundation of a European Research Council (ERC)
8. EC boosts European electron microscopy research
9. Plants for the future: A European vision for plant biotechnology towards 2025
10. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
11. Limited climate tracking in European trees despite 10,000 years of postglacial warmth

Post Your Comments:
(Date:5/24/2013)... for medication against Alzheimer,s disease, scientists have focused among ... beta (A-beta). After all, it is the accumulation of A-beta ... patients. Starting point for the formation of A-beta is APP. ... to unravel the function of APPL the fruit-fly version ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that ...
(Date:5/23/2013)... to be the world,s most popular fruit, can be ... with purple GM varieties. , "Working with GM ... the addition of a specific compound, allows us to ... Professor Cathie Martin from the John Innes Centre. , ... better flavour, health and shelf life characteristics because even ...
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2The world's favorite fruit only better-tasting and longer-lasting 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
(Date:5/23/2013)... May 23, 2013 BioTrends Research Group, ... firms for specialized biopharmaceutical issues, finds that, unaided, ... disease specialists reported that in the past six ... delaying treatment) in anticipation of the next generation ... ago, when only 6 percent reported that they ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
Cached News: